Conflict of Interest Policy Limits Industry Control Over Studies, Publication
Executive Summary
Sponsors will have a limited time to review manuscripts before publication, a revised conflict of interest policy from the major medical journals states.
You may also be interested in...
PhRMA Firms Will Disclose “Ghost Writers,” Give Credit For Journal Work
Manuscript writers and statisticians provided by drug sponsors to help present results from a clinical trial will be "recognized appropriately" as contributors to publications of the data, according to a draft policy paper on the ethics of clinical trials under development by the Pharmaceutical Research & Manufacturers of America
PhRMA Firms Will Disclose “Ghost Writers,” Give Credit For Journal Work
Manuscript writers and statisticians provided by drug sponsors to help present results from a clinical trial will be "recognized appropriately" as contributors to publications of the data, according to a draft policy paper on the ethics of clinical trials under development by the Pharmaceutical Research & Manufacturers of America
Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex
Pharmacia is preparing to publish the full 12-month data from the Celebrex CLASS GI outcomes study.